Pharmacyte Biotech Inc (OTCMKTS:PMCB) announced that one of its Consortium members published a review article about live-cell and gene therapy for the treatment of diabetes. The favorable article was published in the prestigious Nature Journal. The article was authored by Prof. Ann M. Simpson, who collaborated with her colleagues at the University of Technology Sydney (UTS).
Pharmacyte Biotech Inc (OTCMKTS:PMCB) cited the publication of the article as a favorable development, especially given that it highlighted its signature live-cell technology. The company is engaged in the development of innovative technologies for the treatment of deadly diseases such as cancer and diabetes.
The article by Simpson, a member of PMCB’s Diabetes Consortium, highlighted the promise of cell and gene therapies in the treatment of Type 1 diabetes. The article described how the technology can be used to engineer non-pancreatic cells to allow them help with blood sugar regulation by producing insulin.
Insulin from non-pancreatic cells
Melligen cell line, which has already entered preclinical trial, is one of the products that have been developed based on the gene engineering technology described by Simpson in the review article. The development of Melligen involves engineering human non-pancreatic cells that originate from the liver. The cells are then made to produce, store and secrete insulin on demand.
Pharmacyte Biotech Inc (OTCMKTS:PMCB)’s CEO, Kenneth L. Waggoner, said Simpson is a renowned researcher in the field of diabetes. Simpson is also playing a leading role in the research to find a better cure for diabetes. Waggoner further said they were delighted by the publication of the article, especially given that the article was authored by a member of their International Diabetes Consortium.
Partner opens facility in Singapore
Further to the publication of the favorable review article, Pharmacyte Biotech Inc (OTCMKTS:PMCB) also disclosed that one of its research partners has opened a research facility in Singapore. The company said that Austrianova opened a new facility in Biopolis, which is a world-class biomedical research hub. The work to be carried out at the Biopolis facility will support PMCB various studies of diabetes and cancer cures based on its signature live-cell technology.